News

Press Releases

January 12, 2021
Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates
January 6, 2021
Verve Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
November 23, 2020
Verve Therapeutics to Present at the Piper Sandler Annual Virtual Healthcare Conference
November 9, 2020
Verve Therapeutics Announces Presentations on its Gene Editing Approach to Develop Transformative Medicines for Coronary Heart Disease at the American Heart Association Scientific Sessions 2020
See all

Media Contact
Gina Nugent
Ten Bridge Communications
(617) 460-3579
gina@tenbridgecommunications.com

Presentations and Publications

January 12, 2021
Verve Therapeutics Corporate Presentation
39th Annual J.P. Morgan Healthcare Conference
June 27, 2020
Sekar Kathiresan, M.D., Keynote Presentation
International Society for Stem Cell Research Virtual 2020 Meeting
April 8, 2019
Genetics of Common, Complex Coronary Artery Disease
Cell
February 11, 2019
Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing
Nature Biotechnology
See all

In the News

October 1, 2020
BBJ honors 2020 Best Places to Work award winners
Boston Business Journal
September 30, 2020
The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn’t going to stop them
Endpoints News
August 14, 2020
How a biotech CEO figured out Covid-19 surveillance testing for 50 companies with 12-hour turnaround times
CNBC
August 13, 2020
COVID-19 testing to keep employees safe
CNBC
See all
 

Stay Connected

Find us on LinkedIn and Twitter